Loading...

IOVA IOVANCE BIOTHERAPEUTICS INC Operational Disruptions 8-K Filing

VNC

V

IOVANCE BIOTHERAPEUTICS INC

(IOVA)

2024 8-K

Show Summary

Summary

Financial Statements

Management Change

Office Relocation

Corporate Presentation Update

Financial Results

Presentation Update

Earnings Reports

Submission of Marketing Aut...

Annual Meeting of Stockholders

Presentation Update

Clinical Data Announcement

Financial Results Announcement

Settlement of Stockholder D...

Retirement and Nomination

Corporate Presentation Update

Financial Results Announcement

Sale of Common Stock

Underwriting Agreement

Financial Results and FDA A...

Presentation Update

Presentation Update

Earnings Reports

FDA Update on Lifileucel Ta...

Unauthorized Posting of Pre...

Earnings Release

Open Market Sale Agreement

Annual Meeting of Stockholders

FDA Accepts Biologics Licen...

Acquisition of Worldwide Ri...

Earnings Report

Appointment of Director

FDA Submission Completed

Earnings Release

Acquisition of Worldwide Ri...

Corporate Presentation Update

External Links:

Iovance Biotherapeutics, Inc. announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma for the upcoming 2024 American Society of Clinical Oncology Annual Meeting.

AI Assistant

IOVANCE BIOTHERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.